Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Expert Says Melanoma Clinical Trials Should Include More Patients With Brain Mets

December 12th 2017

Harriet Kluger, MD, discussed the lack of clinical trial inclusion for patients with melanoma who have brain metastases, as well as promising regimens coming down the pike.

Dr. Sznol Discusses the Role of Surgery in Melanoma

December 8th 2017

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the role of surgery in the treatment of patients with melanoma.

Dr. Atkins Discusses the Adjuvant Treatment of Melanoma

December 8th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the adjuvant treatment of melanoma.

Dr. Postow Discusses Combination Therapy for Melanoma

December 6th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Ipilimumab Effective in Adolescents With Advanced Melanoma

November 30th 2017

Ipilimumab was associated with a 1-year overall survival rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.

Dr. Atkinson on Novel Combinations in Melanoma

November 30th 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Soyer Discusses the Role of Technology in Melanoma

November 21st 2017

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

Dr. Postow on Entrectinib in Melanoma

November 15th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

Dr. Soyer Discusses Screening for Melanoma

November 10th 2017

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses screening for melanoma.

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

November 10th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma

November 9th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab versus ipilimumab for patients with melanoma.

New Adjuvant Therapy Era Builds in Melanoma

November 6th 2017

Researchers are seeking to determine whether the plethora of new therapies that have been introduced in recent years in the advanced and metastatic settings can benefit patients at risk of recurrence earlier in the treatment timeline for melanoma.

BRAF/MEK Combinations Continue to Revolutionize Melanoma Landscape

November 1st 2017

Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Dr. Saw Discusses Study of Vitamin D in Melanoma

October 31st 2017

Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Glembatumumab Vedotin Induces 61% DCR in Uveal Melanoma

October 27th 2017

Glembatumumab vedotin (CDX-011) induced a disease control rate of 61% in patients with metastatic uveal melanoma, despite a low a low objective response rate of 6%.

Dr. Guitera on the RADICAL Trial for Melanoma

October 25th 2017

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.